BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stock Short Interest Report for October

BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) saw a significant decline in short interest in the month of October. As of October 30th, there was short interest totaling 3,180 shares, a decline of 64.9% from the October 15th total of 9,051 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 3,299 shares, the days-to-cover ratio is presently 1.0 days.

BioNexus Gene Lab Price Performance

Shares of BioNexus Gene Lab stock opened at $0.82 on Monday. BioNexus Gene Lab has a one year low of $0.81 and a one year high of $4.97. The stock’s fifty day moving average is $1.22 and its 200 day moving average is $1.86. The stock has a market cap of $2.41 million, a P/E ratio of -0.65 and a beta of 4.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.28 and a current ratio of 6.08.

BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.12) earnings per share for the quarter. BioNexus Gene Lab had a negative net margin of 82.38% and a negative return on equity of 32.92%. The company had revenue of $0.08 million for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, BioNexus Gene Lab presently has a consensus rating of “Sell”.

Check Out Our Latest Stock Report on BioNexus Gene Lab

About BioNexus Gene Lab

(Get Free Report)

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a biotechnology and molecular diagnostics company focused on using genetic and genomic information to support disease screening, risk assessment and personalized healthcare. The company develops and commercializes diagnostic products and laboratory services based on the analysis of biological samples, including blood and other specimens. Its offerings are intended to help identify potential health risks and support the early detection and management of conditions such as cancer and other diseases.

See Also

Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.